Online inquiry

IVTScrip™ mRNA-Anti-LTA, MLTA3698A(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (CAT#: GTTS-WQ11957MR)

This product GTTS-WQ11957MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets LTA gene. The antibody can be applied in Rheumatoid arthritis (RA) research.

Specifications
Product type	mRNA
Modified bases	N1-Methylpseudo-UTP
5' Cap	Cap 0
Species	Humanized
RefSeq	NM_000595.4
Applications	Gene therapy research
Format	Powder
Quantity	100 µg
Purification	oligo-dT affinity purification

Target Gene
Gene ID	4049
UniProt ID	P01374

Download
Download resources about mRNA therapeutics development to boost your research.

CUSTOMER REVIEWS and Q&As
There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-LTA, MLTA3698A(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ11957MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT	Product Name	Product Type	CDs
GTTS-WQ15759MR	IVTScrip™ mRNA-Anti-CA9, WX-G250(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))	mRNA	WX-G250
GTTS-WQ2791MR	IVTScrip™ mRNA-Anti-IL1RL1, AMG-282(Cap 0, 5-Methyl-CTP, 120 nt-poly(A))	mRNA	AMG-282
GTTS-WQ3420MR	IVTScrip™ mRNA-Anti-HGF, AV-299(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))	mRNA	AV-299
GTTS-WQ2794MR	IVTScrip™ mRNA-Anti-IL1RL1, AMG-282(Cap 1, 5-Methyl-CTP, 30 nt-poly(A))	mRNA	AMG-282
GTTS-WQ4735MR	IVTScrip™ mRNA-Anti-IL21, BOS161721(Cap 0, 5-Methyl-CTP, 120 nt-poly(A))	mRNA	BOS161721
GTTS-WQ1781MR	IVTScrip™ mRNA-Anti-IL2RA, ADCT-301(unconjugated)(Cap 0, 2-Thio-UTP, 30 nt-poly(A))	mRNA	ADCT-301(unconjugated)
GTTS-WQ8888MR	IVTScrip™ mRNA-Anti-IFNA1&IFNB1, IFN-alpha-REC(Cap 1, 2-Thio-UTP, 30 nt-poly(A))	mRNA	IFN-alpha-REC
GTTS-WQ15253MR	IVTScrip™ mRNA-Anti-phosphatidylserine, Tarvacin ch3G4(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A))	mRNA	Tarvacin ch3G4

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST